Huons' reported results peaked in 2023, dipped, and recovered in 2025. Revenue rose from KRW 492.4 billion in 2022 to KRW 552 billion in 2023, up 12.1%, then to KRW 590.2 billion in 2024, up 6.9%, and to KRW 620.8 billion in 2025, up 5.2%, marking three consecutive years of growth from 2023 through 2025.
Operating profit was KRW 56 billion in 2023, the largest year of 2022 to 2025, and KRW 39.7 billion in 2024, down 29.1%, the smallest year. Operating profit in 2025 was KRW 45.6 billion, up 14.9%, with an operating margin of 7.3%, above 6.7% in 2024 but below 10.1% in 2023.
Net income attributable to controlling shareholders was KRW 50.5 billion in 2023, the largest year, and recovered to KRW 42.7 billion in 2025, up 44.8%. Net income including non-controlling interests was KRW 42.2 billion in 2025 and is a different figure from controlling-shareholder net income.
Operating cash flow was KRW 45 billion in 2025, below KRW 52.6 billion in 2024. Quarterly, the fourth quarter of 2025 posted revenue of KRW 165.2 billion, up 7.5% from the prior quarter, and operating profit of KRW 9.82 billion, before the first quarter of 2026 swung to an operating loss of KRW 649 million.
The second quarter returned to operating profit of KRW 2.93 billion, but the third quarter posted revenue of KRW 144 billion, down 6.3% year on year, and an operating loss of KRW 4.47 billion.
The company attributed the sales decline to the end of its continuous glucose monitor business and the absence of US exports, and the profit squeeze to higher cost of sales, R&D spending, and added recall costs on a US export product.
Third-quarter R&D rose 13.9% year on year and 21% from the prior quarter, and cumulative R&D for the first three quarters of 2026 was KRW 7.9 billion, up 24.8%, about 4.9% of sales.
Third-quarter net income attributable to controlling shareholders was KRW 16.1 billion, up 103.8% year on year, moving in the opposite direction from the operating loss; how non-operating items contributed will be checked in the regular report line items. Over the last four quarters, net income attributable to controlling shareholders totaled KRW 2.71 billion.